{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:57:22Z","timestamp":1792112242000,"version":"4.4.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.genhosppsych.2020.08.008","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T19:25:22Z","timestamp":1598124322000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use"],"prefix":"10.1016","volume":"67","author":[{"given":"Scott R.","family":"Beach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne F.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly E.","family":"Hartney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Rundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/10401230591002048","article-title":"The haloperidol story","volume":"17","author":"Granger","year":"2005","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0010","series-title":"Paul Janssen and the discovery of haloperidol and other neuroleptics","volume":"2","author":"CJE","year":"1988"},{"issue":"10","key":"10.1016\/j.genhosppsych.2020.08.008_bb0015","first-page":"878","article-title":"R-1625: a new drug for the symptomatic treatment of psychomotor excitation","volume":"58","author":"Divry","year":"1958","journal-title":"Acta Neurol Psychiatr Belg"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0020","series-title":"The main therapeutic actions of neuroleptic drugs","author":"Hasse","year":"1965"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0025","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0163-8343(79)90025-2","article-title":"Emergency use of intravenous haloperidol","volume":"1","author":"Dudley","year":"1979","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0030","series-title":"The intravenous use of haloperidol for acute delirium in intensive care settings. Psychic and neurological dysfunctions after open heart surgery","first-page":"196","author":"Sos","year":"1980"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0035","first-page":"239","article-title":"Treatment of severe, refractory agitation with a haloperidol drip","volume":"49","author":"Fernandez","year":"1988","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00004714-199104000-00021","article-title":"High-dose intravenous haloperidol for agitated delirium in a cardiac patient on intra-aortic balloon pump","volume":"11","author":"Sanders","year":"1991","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0045","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0033-3182(95)71710-8","article-title":"High-dose intravenous haloperidol for agitated delirium following lung transplantation","volume":"36","author":"Levenson","year":"1995","journal-title":"Psychosomatics"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0050","first-page":"156","article-title":"Practice guideline for the treatment of patients with delirium","author":"Trzepacz","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.genhosppsych.2020.08.008_bb0055","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/jgs.15640","article-title":"Preventing postoperative delirium after major noncardiac thoracic surgery-a randomized clinical trial","volume":"66","author":"Khan","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/BF02244824","article-title":"Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol","volume":"106","author":"Chang","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0065","first-page":"215","article-title":"Using intravenous haloperidol to control delirium","volume":"43","author":"Gelfand","year":"1992","journal-title":"Hosp Community Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0447.1984.tb01198.x","article-title":"High-dose neuroleptics for acute brain failure after intensive chemotherapy for acute leukemia","volume":"70","author":"Andersson","year":"1984","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0075","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12028-011-9643-3","article-title":"Haloperidol dosing strategies in the treatment of delirium in the critically ill","volume":"16","author":"Wang","year":"2012","journal-title":"Neurocrit Care"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0080","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/clpt.1983.65","article-title":"Haloperidol kinetics after oral and intravenous doses","volume":"33","author":"Holley","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4155\/fmc-2017-0164","article-title":"Novel Sigma-1 receptor antagonists: from opioids to small molecules: what is new?","volume":"10","author":"Arena","year":"2018","journal-title":"Future Med Chem"},{"issue":"6401","key":"10.1016\/j.genhosppsych.2020.08.008_bb0090","first-page":"1264","article-title":"Malignant ventricular tachyarrhythmia and haloperidol","volume":"287","author":"Bett","year":"1983","journal-title":"Br Med J"},{"issue":"8610","key":"10.1016\/j.genhosppsych.2020.08.008_bb0095","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(88)92689-X","article-title":"Haloperidol and cardiac arrest","volume":"2","author":"Huyse","year":"1988","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0100","first-page":"178","article-title":"Sinusbradykardie, QT-Verl\u00e4ngerung und Kammerflimmern unter Haloperidol-und Clonidin-Therapie des Alkoholentzugssyndroms","volume":"29","author":"Rettmar","year":"1992","journal-title":"Intensivmedizin+ Notfallmedizin"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0105","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00004714-199304000-00007","article-title":"Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill","volume":"13","author":"Metzger","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0110","author":"Administration, U.S.F.a.D"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0120","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/CCM.0000000000001411","article-title":"Preventing ICU subsyndromal delirium conversion to delirium with low-dose IV haloperidol: a double-blind, placebo-controlled pilot study","volume":"44","author":"Al-Qadheeb","year":"2016","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.genhosppsych.2020.08.008_bb0125","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1007\/s00134-016-4512-3","article-title":"The use of low-dose IV haloperidol is not associated with QTc prolongation: post hoc analysis of a randomized, placebo-controlled trial","volume":"42","author":"Duprey","year":"2016","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0130","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1399-6576.1962.tb00102.x","article-title":"Haloperidol (Serenase) in the prevention of postoperative nausea and vomiting","volume":"6","author":"Dyrberg","year":"1962","journal-title":"Acta Anaesthesiol Scand"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2190\/FWJP-2YPC-JPFA-LM3N","article-title":"Management of delirium in terminally ill AIDS patients","volume":"19","author":"Fernandez","year":"1989","journal-title":"Int J Psychiatry Med"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0140","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1200\/JCO.1984.2.7.782","article-title":"Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study","volume":"2","author":"Grunberg","year":"1984","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0145","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF03022656","article-title":"Haloperidol is as effective as ondansetron for preventing postoperative nausea and vomiting","volume":"54","author":"Lee","year":"2007","journal-title":"Can J Anaesth"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1985.tb02840.x","article-title":"Mood alteration following oral and intravenous haloperidol and relationship to drug concentration in normal subjects","volume":"25","author":"Magliozzi","year":"1985","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0155","first-page":"278","article-title":"Decreased extrapyramidal symptoms with intravenous haloperidol","volume":"48","author":"Menza","year":"1987","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0160","first-page":"238","article-title":"Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines","volume":"17","author":"Menza","year":"1988","journal-title":"Heart Lung"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0165","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-2600(13)70166-8","article-title":"Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial","volume":"1","author":"Page","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1001\/jama.2018.0160","article-title":"Effect of haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial","volume":"319","author":"van den Boogaard","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.genhosppsych.2020.08.008_bb0175","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1176\/ajp.154.10.1474b","article-title":"Extrapyramidal symptoms from intravenous haloperidol in the treatment of delirium","volume":"154","author":"Blitzstein","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0180","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/00005373-199510000-00038","article-title":"Neuroleptic malignant syndrome in a trauma patient","volume":"39","author":"Burke","year":"1995","journal-title":"J Trauma"},{"issue":"1_suppl","key":"10.1016\/j.genhosppsych.2020.08.008_bb0185","first-page":"32","article-title":"High-dose treatment with neuroleptics in the acute phase of mental disease","volume":"69","author":"Dencker","year":"1976","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0190","first-page":"2013","article-title":"Neuroleptic malignant syndrome associated with haloperidol use in critical care setting: should haloperidol still be considered the drug of choice for the management of delirium in the critical care setting?","author":"Dixit","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0195","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1177\/0897190011420159","article-title":"Neuroleptic-induced catatonia in two hospitalized patients","volume":"25","author":"Gugger","year":"2012","journal-title":"J Pharm Pract"},{"issue":"9","key":"10.1016\/j.genhosppsych.2020.08.008_bb0200","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/070674379003500914","article-title":"Neuroleptic malignant syndrome with intravenous haloperidol","volume":"35","author":"Levitt","year":"1990","journal-title":"Can J Psychiatry"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0205","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF01708104","article-title":"Neuroleptic malignant syndrome in a patient with head injury","volume":"22","author":"Perez-Vela","year":"1996","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4103\/1793-5482.92173","article-title":"Neuroleptic malignant syndrome and closed head injury: a case report and review","volume":"6","author":"Shaikh","year":"2011","journal-title":"Asian J Neurosurg"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1176\/ajp.120.4.389","article-title":"Haloperidol in the treatment of 120 psychotic patients","volume":"120","author":"Danik","year":"1963","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0220","first-page":"1","article-title":"QTc prolongation after haloperidol administration in critically ill patients post cardiovascular surgery: a cohort study and review of the literature","author":"Burbuqe","year":"2020","journal-title":"Palliat Support Care"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0225","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1213\/ane.0b013e3181609424","article-title":"The prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy","volume":"106","author":"Chu","year":"2008","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0230","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jemermed.2015.03.023","article-title":"A randomized controlled trial of intravenous haloperidol vs. intravenous metoclopramide for acute migraine therapy in the emergency department","volume":"49","author":"Gaffigan","year":"2015","journal-title":"J Emerg Med"},{"issue":"26","key":"10.1016\/j.genhosppsych.2020.08.008_bb0235","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","article-title":"Haloperidol and ziprasidone for treatment of delirium in critical illness","volume":"379","author":"Girard","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0240","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1213\/ane.0b013e31816091f0","article-title":"Haloperidol plus ondansetron versus ondansetron alone for prophylaxis of postoperative nausea and vomiting","volume":"106","author":"Grecu","year":"2008","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0245","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004714-200106000-00002","article-title":"The association between intravenous haloperidol and prolonged QT interval","volume":"21","author":"Hatta","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0250","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11096-011-9541-y","article-title":"Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case","volume":"33","author":"Meyer-Massetti","year":"2011","journal-title":"Int J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0255","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/11599960-000000000-00000","article-title":"Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol","volume":"35","author":"Muzyk","year":"2012","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0260","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","article-title":"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia","volume":"34","author":"Ozeki","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0265","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/cc7890","article-title":"Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial","volume":"13","author":"Reade","year":"2009","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40211-014-0097-7","article-title":"QTc prolongation induced by intravenous sedation with haloperidol, prothipendyl and lorazepam","volume":"28","author":"Scharfetter","year":"2014","journal-title":"Neuropsychiatr"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0275","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0002-9149(97)00888-6","article-title":"Torsades de Pointes associated with intravenous haloperidol in critically ill patients","volume":"81","author":"Sharma","year":"1998","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1592\/phco.27.2.175","article-title":"Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol","volume":"27","author":"Tisdale","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.genhosppsych.2020.08.008_bb0285","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/00912700122012896","article-title":"The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes","volume":"41","author":"Tisdale","year":"2001","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0290","doi-asserted-by":"crossref","first-page":"R9","DOI":"10.1186\/cc11933","article-title":"Haloperidol prophylaxis in critically ill patients with a high risk for delirium","volume":"17","author":"van den Boogaard","year":"2013","journal-title":"Crit Care"},{"issue":"12","key":"10.1016\/j.genhosppsych.2020.08.008_bb0295","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/11318880-000000000-00000","article-title":"Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly","volume":"26","author":"Vieweg","year":"2009","journal-title":"Drugs Aging"},{"issue":"9","key":"10.1016\/j.genhosppsych.2020.08.008_bb0300","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/BF03261969","article-title":"A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients","volume":"35","author":"Muzyk","year":"2012","journal-title":"Drug Saf"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0305","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1161\/CIRCOUTCOMES.113.000651","article-title":"Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients","volume":"7","author":"Tisdale","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0310","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/amiajnl-2014-002777","article-title":"Don\u2019t fuel the fire: decreasing intravenous haloperidol use in high risk patients via a customized electronic alert","volume":"21","author":"Pell","year":"2014","journal-title":"J Am Med Inform Assoc"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0315","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/jgs.12049","article-title":"Unsafe use of intravenous haloperidol: evaluation of recommendation-concordant care in hospitalized elderly adults","volume":"61","author":"Cheung","year":"2013","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0320","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/phar.1242","article-title":"Agreement between ICU clinicians and electrophysiology cardiologists on the decision to initiate a QTc-interval prolonging medication in critically ill patients with potential risk factors for torsade de pointes: a comparative, case-based evaluation","volume":"33","author":"Fongemie","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0325","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1592\/phco.24.4.404.33172","article-title":"Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient","volume":"24","author":"Akers","year":"2004","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0330","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/clc.4960180512","article-title":"Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients","volume":"18","author":"Di Salvo","year":"1995","journal-title":"Clin Cardiol"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0335","first-page":"352","article-title":"Corrected QT interval prolongation associated with intravenous haloperidol in acute coronary syndromes","volume":"50","author":"Douglas","year":"2000","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0340","first-page":"822","article-title":"Torsade de pointes complicating the treatment of bleeding esophageal varices: association with neuroleptics, vasopressin, and electrolyte imbalance","volume":"90","author":"Faigel","year":"1995","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0345","first-page":"48","article-title":"Torsade de pointes following intravenous haloperidol administration in a patient with complete heart block","volume":"108","author":"Ginwalla","year":"2009","journal-title":"WMJ"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0210-5691(04)70023-6","article-title":"Haloperidol por v\u00eda intravenosa y torsade de pointes","volume":"28","author":"Herrero-Hern\u00e1ndez","year":"2004","journal-title":"Med Intensiva"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0355","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0033-3182(95)71609-7","article-title":"The association between intravenous haloperidol and Torsades de Pointes. Three cases and a literature review","volume":"36","author":"Hunt","year":"1995","journal-title":"Psychosomatics"},{"issue":"10","key":"10.1016\/j.genhosppsych.2020.08.008_bb0360","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1345\/aph.19017","article-title":"Haloperidol-induced torsade de pointes","volume":"33","author":"O\u2019Brien","year":"1999","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0365","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03018922","article-title":"Torsades de pointes secondary to intravenous haloperidol after coronary bypass grafting surgery","volume":"47","author":"Perrault","year":"2000","journal-title":"Can J Anaesth"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0370","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00003246-199403000-00013","article-title":"Continuous infusion of haloperidol controls agitation in critically ill patients","volume":"22","author":"Riker","year":"1994","journal-title":"Crit Care Med"},{"issue":"10","key":"10.1016\/j.genhosppsych.2020.08.008_bb0375","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1111\/j.1532-5415.2008.01901.x","article-title":"Low-dose haloperidol-associated QTc prolongation","volume":"56","author":"Stepkovitch","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0380","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-119-5-199309010-00007","article-title":"Torsade de pointes associated with the use of intravenous haloperidol","volume":"119","author":"Wilt","year":"1993","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0385","first-page":"109","article-title":"Torsades de pointes: potential consequence of intravenous haloperidol in the intensive care unit","volume":"11","author":"Zeifman","year":"1994","journal-title":"Intensive Care World"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0390","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1440-1819.2007.01709.x","article-title":"Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature","volume":"61","author":"Katagai","year":"2007","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0395","first-page":"68","article-title":"Three cases of ventricular tachycardia and torsades de pointes induced by antipsychotic drugs","volume":"29","author":"Arita","year":"1997","journal-title":"Shinzo"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0400","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0163-8343(91)90106-7","article-title":"Intravenous haloperidol treatment of severely regressed, nonviolent psychiatric inpatients","volume":"13","author":"Plotnick","year":"1991","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2020.08.008_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0410","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.psym.2017.10.009","article-title":"QT prolongation, Torsades de Pointes, and psychotropic medications: a 5-year update","volume":"59","author":"Beach","year":"2018","journal-title":"Psychosomatics"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0415","doi-asserted-by":"crossref","unstructured":"Glassman, A.H. and J.T. Bigger, Jr., Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry, 2001. 158(11): p. 1774\u201382.","DOI":"10.1176\/appi.ajp.158.11.1774"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0420","first-page":"543","article-title":"Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use","volume":"2","author":"Hassaballa","year":"2003","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.genhosppsych.2020.08.008_bb0425","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/j.1875-9114.1997.tb03061.x","article-title":"Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature","volume":"17","author":"Lawrence","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0430","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/jhm.691","article-title":"The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?","volume":"5","author":"Meyer-Massetti","year":"2010","journal-title":"J Hosp Med"},{"issue":"11","key":"10.1016\/j.genhosppsych.2020.08.008_bb0435","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2146\/ajhp070279","article-title":"Association of antipsychotic and antidepressant drugs with Q-T interval prolongation","volume":"65","author":"Zemrak","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0440","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00004714-198505060-00009","article-title":"Use of high-dose intravenous haloperidol in the treatment of agitated cardiac patients","volume":"5","author":"Tesar","year":"1985","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.genhosppsych.2020.08.008_bb0445","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s00134-018-5204-y","article-title":"Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study","volume":"44","author":"Collet","year":"2018","journal-title":"Intensive Care Med"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0450","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/ajp.2007.164.6.870","article-title":"Neuroleptic malignant syndrome","volume":"164","author":"Strawn","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.genhosppsych.2020.08.008_bb0455","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.1989.01810100056011","article-title":"Risk factors for neuroleptic malignant syndrome. A case-control study","volume":"46","author":"Keck","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"10.1016\/j.genhosppsych.2020.08.008_bb0460","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1017\/S0140525X02000109","article-title":"What catatonia can tell us about \u201ctop-down modulation\u201d: a neuropsychiatric hypothesis","volume":"25","author":"Northoff","year":"2002","journal-title":"Behav Brain Sci"},{"key":"10.1016\/j.genhosppsych.2020.08.008_bb0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.genhosppsych.2017.06.011","article-title":"Alternative treatment strategies for catatonia: a systematic review","volume":"48","author":"Beach","year":"2017","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0470","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.psym.2018.07.010","article-title":"Catatonia due to clozapine withdrawal: a case report and literature review","volume":"60","author":"Boazak","year":"2019","journal-title":"Psychosomatics"},{"issue":"4","key":"10.1016\/j.genhosppsych.2020.08.008_bb0475","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0033-3182(10)70710-6","article-title":"Clozapine-withdrawal catatonia","volume":"51","author":"Wadekar","year":"2010","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.genhosppsych.2020.08.008_bb0480","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.genhosppsych.2020.08.008_bb0485","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.hrthm.2015.11.008","article-title":"Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: findings from the Penn Atrial Fibrillation Free study","volume":"13","author":"Patel","year":"2016","journal-title":"Heart Rhythm"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834320301213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834320301213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:51:38Z","timestamp":1759013498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834320301213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":97,"alternative-id":["S0163834320301213"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.08.008","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2020.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}